Literature DB >> 11293947

Analysis of volatile organic compounds: possible applications in metabolic disorders and cancer screening.

J Rieder1, P Lirk, C Ebenbichler, G Gruber, P Prazeller, W Lindinger, A Amann.   

Abstract

The human breath contains a variety of endogenous volatile organic compounds (VOCs). The origin and pathophysiological importance of these VOCs is poorly investigated. Little is known about the interaction of VOCs from ambient air, such as those produced by plants and exhaust fumes, with the human organism. Gas chromatographic determination of VOC concentrations is tedious. Proton-transfer-mass spectroscopy (PTR-MS), a new technology for the online detection of VOC patterns, is a valuable alternative. We present two interesting molecular species, isoprene and ortho (o)-toluidine, as examples of endogenously produced VOCs. In a case study, breath isoprene reductions during lipid-lowering therapy (36%) were shown to correlate with cholesterol (32%) and LDL concentrations (35%) in blood (p < 0.001) over a period of 15 days. Therefore, isoprene concentrations in human breath (measured by PTR-MS) might serve as an additional parameter to complement invasive tests for controlling lipid-lowering therapy. Furthermore, it may be a useful parameter for lipid disorder screening. Mass-108, which presumably represents o-toluidine in our breath samples, was found in significantly higher concentrations in the breath of patients with different tumors (1.5 +/- 0.8 ppbv) than in age-matched controls (0.24 +/- 0.1 ppbv, p < 0.001). Inflammatory reactions do not seem to alter the pattern of mass-108. Therefore, it appears to be a currently underestimated carcinoma marker that deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11293947

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  8 in total

1.  Exhaled breath analysis: from occupational to respiratory medicine.

Authors:  Massimo Corradi; Antonio Mutti
Journal:  Acta Biomed       Date:  2005

2.  A mathematical model for breath gas analysis of volatile organic compounds with special emphasis on acetone.

Authors:  Julian King; Karl Unterkofler; Gerald Teschl; Susanne Teschl; Helin Koc; Hartmann Hinterhuber; Anton Amann
Journal:  J Math Biol       Date:  2011-01-14       Impact factor: 2.259

3.  Antifungal activity of volatile compounds-producing Pseudomonas P2 strain against Rhizoctonia solani.

Authors:  Salem Elkahoui; Naceur Djébali; Najeh Yaich; Sana Azaiez; Majdi Hammami; Rym Essid; Ferid Limam
Journal:  World J Microbiol Biotechnol       Date:  2014-11-11       Impact factor: 3.312

Review 4.  The clinical potential of exhaled breath analysis for diabetes mellitus.

Authors:  Timothy Do Chau Minh; Donald Ray Blake; Pietro Renato Galassetti
Journal:  Diabetes Res Clin Pract       Date:  2012-03-10       Impact factor: 5.602

5.  Exhaled methyl nitrate as a noninvasive marker of hyperglycemia in type 1 diabetes.

Authors:  B J Novak; D R Blake; S Meinardi; F S Rowland; A Pontello; D M Cooper; P R Galassetti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-25       Impact factor: 11.205

6.  Assessment of the exhalation kinetics of volatile cancer biomarkers based on their physicochemical properties.

Authors:  Anton Amann; Pawel Mochalski; Vera Ruzsanyi; Yoav Y Broza; Hossam Haick
Journal:  J Breath Res       Date:  2014-02-24       Impact factor: 3.262

7.  Quantification of recent smoking behaviour using proton transfer reaction-mass spectrometry (PTR-MS).

Authors:  Philipp Lirk; Florian Bodrogi; Martina Deibl; Christian M Kähler; Joshua Colvin; Berthold Moser; Germar Pinggera; Hartmann Raifer; Josef Rieder; Wolfgang Schobersberger
Journal:  Wien Klin Wochenschr       Date:  2004-01-31       Impact factor: 2.275

Review 8.  Detection of cancer through exhaled breath: a systematic review.

Authors:  Agne Krilaviciute; Jonathan Alexander Heiss; Marcis Leja; Juozas Kupcinskas; Hossam Haick; Hermann Brenner
Journal:  Oncotarget       Date:  2015-11-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.